GLENMARK PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLENMARK PHARMACEUTICALS have increased by 12.44% YoY .
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has decreased by -68.44 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
GLENMARK PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 532296|NSE : GLENMARK]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹12,305 Cr | ₹10,944 Cr | ₹10,641 Cr | ₹9,865 Cr | ₹9,074 Cr |
| Expenses | ₹9,985 Cr | ₹8,860 Cr | ₹8,943 Cr | ₹8,280 Cr | ₹7,459 Cr |
| Operating Profit (Excl OI) | ₹2,320 Cr | ₹2,084 Cr | ₹1,698 Cr | ₹1,586 Cr | ₹1,615 Cr |
| Other Income | ₹167 Cr | ₹50 Cr | ₹160 Cr | ₹208 Cr | ₹91 Cr |
| Interest | ₹298 Cr | ₹353 Cr | ₹377 Cr | ₹335 Cr | ₹286 Cr |
| Depreciation | ₹487 Cr | ₹444 Cr | ₹417 Cr | ₹326 Cr | ₹302 Cr |
| Profit Before Tax | ₹1,441 Cr | ₹1,382 Cr | ₹1,096 Cr | ₹1,301 Cr | ₹1,119 Cr |
| Profit After Tax | ₹994 Cr | ₹970 Cr | ₹776 Cr | ₹925 Cr | ₹804 Cr |
| Consolidated Net Profit | ₹942 Cr | ₹970 Cr | ₹776 Cr | ₹925 Cr | ₹804 Cr |
| Earnings Per Share (Rs) | ₹10.53 | ₹33.37 | ₹34.38 | ₹27.50 | ₹32.78 |
| PAT Margin (%) | 1.27 | 3.57 | 3.84 | 7.29 | 9.38 |
| ROE(%) | 4.07 | 12.33 | 14.81 | 13.32 | 17.21 |
| ROCE(%) | 9.17 | 14.19 | 15.30 | 14.04 | 16.47 |
| Total Debt/Equity(x) | 0.46 | 0.40 | 0.67 | 0.80 | 0.80 |
Key Financials |
||
| Market Cap | : | ₹ 30,479.0 Cr |
| Revenue (TTM) | : | ₹ 12,489.4 Cr |
| Net Profit(TTM) | : | ₹ -859.9 Cr |
| EPS (TTM) | : | ₹ -30.5 |
| P/E (TTM) | : | - |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 3.8% | 13.6% | 108.9% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
GLENMARK PHARMACEUTICALS Revenues
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 12.44 % |
| 5 Yr CAGR | 7.91 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹12,305 Cr | 12.44 | |
| Mar2022 | ₹10,944 Cr | 2.85 | |
| Mar2021 | ₹10,641 Cr | 7.86 | |
| Mar2020 | ₹9,865 Cr | 8.72 | |
| Mar2019 | ₹9,074 Cr | - | |
GLENMARK PHARMACEUTICALS Operating Profit
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 11.32 % |
| 5 Yr CAGR | 9.48 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹2,320 Cr | 11.32 | |
| Mar2022 | ₹2,084 Cr | 22.75 | |
| Mar2021 | ₹1,698 Cr | 7.08 | |
| Mar2020 | ₹1,586 Cr | -1.83 | |
| Mar2019 | ₹1,615 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -1.00 % |
| 5 Yr CAGR | 1.46 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 18.86% | -1.00 | |
| Mar2022 | 19.05% | 19.36 | |
| Mar2021 | 15.96% | -0.68 | |
| Mar2020 | 16.07% | -9.72 | |
| Mar2019 | 17.8% | - | |
GLENMARK PHARMACEUTICALS Profit After Tax
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -2.92 % |
| 5 Yr CAGR | 4.04 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹942 Cr | -2.92 | |
| Mar2022 | ₹970 Cr | 25.01 | |
| Mar2021 | ₹776 Cr | -16.11 | |
| Mar2020 | ₹925 Cr | 15.08 | |
| Mar2019 | ₹804 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -64.43 % |
| 5 Yr CAGR | -39.34 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 1.27 % | -64.43 | |
| Mar2022 | 3.57 % | -7.03 | |
| Mar2021 | 3.84 % | -47.33 | |
| Mar2020 | 7.29 % | -22.28 | |
| Mar2019 | 9.38 % | - | |
GLENMARK PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -68.44 % |
| 5 Yr CAGR | -24.72 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹11 | -68.44 | |
| Mar2022 | ₹33 | -2.94 | |
| Mar2021 | ₹34 | 25.02 | |
| Mar2020 | ₹28 | -16.11 | |
| Mar2019 | ₹33 | - | |
GLENMARK PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -35.38 % |
| 5 Yr CAGR | -13.62 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 9.17% | -35.38 | |
| Mar2022 | 14.19% | -7.25 | |
| Mar2021 | 15.3% | 8.97 | |
| Mar2020 | 14.04% | -14.75 | |
| Mar2019 | 16.47% | - | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹1,080.1 |
| Current MarketCap | : | ₹ 30,479.0 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 3.8% |
13.6% |
108.9% |
| SENSEX | 0.9% |
1.5% |
23.6% |
GLENMARK PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MOMENTUM | 4.4% | 9.1% | 82.6% |
| S&P BSE 250 SMALLCAP | 4.1% | 11.8% | 66.8% |
| S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
| S&P BSE MID CAP | 4% | 7.6% | 67.4% |
| S&P BSE 400 MIDSMALLCAP | 3.8% | 9.1% | 62% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY FREE SMALL 100 | 4.4% | 13.5% | 81.2% |
| NIFTY SMALLCAP250 | 4.3% | 12.6% | 73.2% |
| NIFTY MID SMALL400 | 3.9% | 9.6% | 64.8% |
| NIFTY SMALLCAP 50 | 3.4% | 13.4% | 83.7% |
| NIFTY HEALTHCARE | 3.2% | 2.5% | 51.3% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS Financials
How the annual revenues of GLENMARK PHARMACEUTICALS have changed ?
The Revenues of GLENMARK PHARMACEUTICALS have increased by 12.44% YoY .
How the Earnings per Share (EPS) of GLENMARK PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has decreased by -68.44 % YoY .
Check out Intrinsic Value of Peers of GLENMARK PHARMACEUTICALS
Compare Stock Analytics of Peers of GLENMARK PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
